| 前收市價 | 0.2000 |
| 開市 | 0.1800 |
| 買盤 | 0.1500 |
| 賣出價 | 0.4000 |
| 拍板 | 3.00 |
| 到期日 | 2024-05-17 |
| 今日波幅 | 0.1500 - 0.4600 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 1.58k |
ZacksIonis (IONS), Biogen Down on Ending Development of ALS Drug
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
- Zacks
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
Per the FDA, the data submitted by Ascendis (ASND) for its hormone replacement therapy constitutes a major amendment to its previously-submitted data. A final decision is expected by Aug 14.
Insider MonkeyHeron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript May 7, 2024 Heron Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.0209, expectations were $-0.08. HRTX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by. My […]
